@jeffmarc Yes, that's the 2019 Khalif study I referenced, confirming your point that if you're going to sequence with mCRPC, it's better to do Abiraterone -> Enzalutamide rather than the other way around.

Unfortunately, it doesn't look at the impact of sequencing on developing castrate resistance in the first place, because the lutamides weren't used yet on-label for mCSPC during the time they collected the study data (AFAIK). Doublet therapy for metastatic castrate-sensitive PCa mainly post-dates that.